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PPulmonary Vascular Disease
Transplantation of Autologous Endothelial
Progenitor Cells May Be Beneficial in Patients
With Idiopathic Pulmonary Arterial Hypertension
A Pilot Randomized Controlled Trial
Xing-Xiang Wang, MD, PHD, Fu-Rong Zhang, MD, Yun-Peng Shang, MD, PHD, Jun-Hui Zhu, MD,
Xu-Dong Xie, MD, PHD, Qian-Min Tao, MD, Jian-Hua Zhu, MD, Jun-Zhu Chen, MD
Hangzhou, China
Objectives The goal of this study was to investigate the feasibility, safety, and initial clinical outcome of intravenous infu-
sion of autologous endothelial progenitor cells (EPCs) in patients with idiopathic pulmonary arterial hypertension
(IPAH).
Background Experimental data suggest that transplantation of EPCs attenuates monocrotaline-induced pulmonary hyperten-
sion in rats and dogs. In addition, clinical studies suggest that autologous progenitor cell transplantation is feasi-
ble and safe in patients with ischemic diseases.
Methods We conducted a prospective, randomized trial comparing the effects of EPC transplantation plus conventional
therapy with those of conventional therapy alone in patients with IPAH. The primary end point was change in the
6-min walk distance using a standardized protocol. The secondary end points were changes in hemodynamic
variables as assessed by right heart catheterization.
Results After 12 weeks of follow-up, the mean distance walked in 6 min increased by 48.2 m in the cell infusion group
(from 263  42 m to 312  34 m), and an increase of 5.7 m occurred in the conventional therapy group (from
264  42 m to 270  44 m). The mean difference between the 2 groups was 42.5 m (95% confidence interval
28.7 to 56.3 m, p  0.001). The patients in the cell infusion group also had significant improvement in mean
pulmonary artery pressure, pulmonary vascular resistance, and cardiac output. There were no severe adverse
events with cell infusion.
Conclusions This preliminary study showed that intravenous infusion of autologous EPCs seemed to be feasible and safe, and
might have beneficial effects on exercise capacity and pulmonary hemodynamics in patients with IPAH. (Safety
and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension; http://
www.clinicaltrials.gov/ct/show/NCT00257413?order1; NCT00257413). (J Am Coll Cardiol 2007;49:
1566–71) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.12.037b
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mdiopathic pulmonary arterial hypertension (IPAH), for-
erly known as primary pulmonary hypertension (PPH), is
rare disorder of unknown etiology characterized by raised
ulmonary artery pressures with pathological changes in
recapillary pulmonary artery. The median life expectancy
rom the time of diagnosis in patients with this disease,
rom the Department of Cardiology, First Affiliated Hospital, College of Medicine,
hejiang University, Hangzhou, China. Supported by the Key Medicine and Health
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f the article. Dr. Chen received a research grant from the Health Bureau of Zhejiang
rovince.w
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006, accepted December 8, 2006.efore the availability of disease-specific (targeted) therapy
1–3), was 2.8 years through the mid-1980s. Modern
reatment has markedly improved physical function and has
xtended survival, and the 5-year mortality rate is 50% (4).
owever, we still do not understand what initiates the
isease or what allows it to progress. There is no cure for the
isease (5). Thus, a novel therapeutic strategy is desirable.
See page 1572
Impairment of vascular and endothelial homeostasis is
hought to play a major role in the initiation and develop-
ent of IPAH (5,6). Many of the perturbations associated
ith the endothelial dysfunction promote vascular remod-
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hus, pulmonary endothelial cells may be a therapeutic
arget for the treatment of IPAH.
Endothelial dysfunction ultimately represents an imbal-
nce between the magnitude of injury and the capacity for
epair (7). A variety of evidence suggests that endothelial
rogenitor cells (EPCs) constitute one aspect of the endo-
helial repair process (7). The EPCs are a cell population
hat has the capacity to circulate, proliferate, and differen-
iate into mature endothelial cells, but have neither acquired
haracteristic mature endothelial markers nor formed a lumen
8). These cells express some, but not all, cell surface markers
haracteristic of mature endothelium, certain surface
arkers of hematopoietic cells, and transcription factors
hat identify them as precursor cells. Laboratory evidence
uggests that these precursors participate in postnatal
eovascularization and re-endothelialization (8–10). Ex-
erimental data have suggested that transplantation of
PCs attenuated monocrotaline-induced pulmonary hyper-
ension in the rat model (11,12). Recently, Takahashi et al.
13) reported that transplantation of autologous EPCs gave
ignificant improvement in mean pulmonary artery pressure,
ardiac output, and pulmonary vascular resistance in the dog
ehydromonocrotaline model. In addition, clinical investi-
ations suggest that autologous progenitor cell transplanta-
ion is feasible and safe in patients with ischemic diseases
14–16).
The feasibility, safety, and efficacy of autologous EPC
ransplantation in patients with IPAH are unknown.
herefore, we investigated the feasibility, safety, and initial
linical outcome of intravenous infusion of autologous
PCs in patients with IPAH.
ethods
atients. Sporadic patients with IPAH between 18 and 60
ears of age of either gender were invited to participate in
he study. The definition of IPAH was pulmonary hyper-
ension unexplained by any secondary cause, on the basis of
he criteria of the National Institutes of Health registry (17).
he diagnosis of IPAH was based on clinical assessment,
ight heart catheterization, echocardiography, spiral com-
uted tomography of the pulmonary arteries, pulmonary
ngiography, ventilation/perfusion lung scan, and complete
ung function testing. Patients were included in the study if
hey were in New York Heart Association functional class II
o III, and had a mean pulmonary artery pressure 30 mm
g on right heart catheterization. Additional inclusion
riteria included the ability to walk 50 m during a
tandardized 6-min walk test. Pulmonary hypertension as a
esult of heart disease, pulmonary disease, sleep-associated
isorders, chronic thromboembolic disease, autoimmune or
ollagen vascular disease, HIV infection, liver disease, New
ork Heart Association functional class IV, major bleeding
equiring blood transfusion, diabetes, renal dysfunction, and
vidence for malignant diseases were excluded. mtudy protocol. The primary
nd point of the randomized
tudy was the change from base-
ine in exercise capacity at the
nd of the study. Exercise capac-
ty was determined by the 6-min
alk test. The secondary end
oints included hemodynamic
ariables (mean pulmonary artery
ressure, pulmonary vascular re-
istance, and cardiac output) as
ssessed by right heart catheter-
zation. After the 6-min walk
est and right heart catheterization at baseline, all patients
ere randomized to receive either conventional therapy
oral calcium blockers, diuretics, nitrates, digoxin, oxygen,
rostaglandin E1, warfarin, and sildenafil) or cell infusions
lus conventional therapy. At our center, calcium blockers
ere administered empirically. In China, neither intrave-
ous prostacyclin nor aerosolized iloprost was licensed for
he treatment of pulmonary hypertension until April 2006.
andomization was performed on the basis of random
umbers, and a completely random design was used in this
rial.
Clinical data, medication, and safety data were prospec-
ively collected. Patients were followed up every 4 weeks for
2 weeks, and staff were continuously available via telephone
or adverse event monitoring. After 12 weeks, the 6-min
alk test and right heart catheterization were repeated.
The study protocol was approved by the ethics review
oard of the First Affiliated Hospital, College of Medicine,
hejiang University, China. Written informed consent was
btained from all participants, and all of the procedures
ere done in accordance with the Declaration of Helsinki
nd relevant policies in China.
xercise capacity and hemodynamics. The 6-min walk
est was performed in all patients using a standardized
rotocol in accordance with the American Thoracic Society
tatement 2002 (18). Patients walked along an enclosed-
evel corridor, and length to first turnaround point was
0 m. Technicians did not escort but encouraged patients
sing standard phrases such as “You are going well,” “Keep
p the good work,” and were instructed not to use other
ncouragement. All patients were told to use their own pace,
ut to cover as much ground as possible in 6 min.
In all patients, a Swan-Ganz catheter (Arrow Deutschland
mbh, Erding, Germany) and an arterial catheter (Angio-
ath, BD, Sandy, Utah) were inserted into the right internal
ugular and right radial artery, respectively. Hemodynamic
easurements were performed in recumbent position. Con-
inuous monitoring included heart rate, systemic and pul-
onary artery blood pressures, and transcutaneous oxygen
aturation. Additional parameters were pressures in wedge
osition and right atrium. Cardiac output was obtained
sing triplicate measurements with the thermodilution
Abbreviations
and Acronyms
EPC  endothelial
progenitor cell
IPAH  idiopathic pulmonary
arterial hypertension
MNC  mononuclear cell
PPH  primary pulmonary
hypertension
VEGF  vascular endothelial
growth factorethod (Agilent, Boeblingen, Germany). Pulmonary vas-
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Progenitor Cells and Pulmonary Hypertension April 10, 2007:1566–71ular resistance and systemic vascular resistance were calcu-
ated according to the standard formulas. Acute hemody-
amic changes, which constitute evidence of vasoreactivity,
ere not examined at our center.
Both the walk test and right heart catheterization were
dministered by personnel who were unaware of the study
rotocol.
reparation and transplantation of EPCs. In patients
eceiving cell infusion, 250 ml of venous blood was collected
mmediately after random assignment. The EPCs were
solated, purified, ex vivo cultured, and characterized ac-
ording to previously described techniques (7,16,19–22).
riefly, mononuclear cells (MNCs) were isolated from
eripheral blood of patients by Ficoll density gradient
entrifugation and cultured on fibronectin-coated (Chemi-
on, Temecula, California) dishes in Medium 199 (Sigma,
t. Louis, Missouri) supplemented with 20% human serum
rawn from each individual patient and vascular endothelial
rowth factor (VEGF, 50 ng/ml, Chemicon). After 5 days
n culture, cells were detached with 0.5 mmol/l ethylenedia-
inetetraacetic acid, washed 3 times with heparinized saline
efore final resuspension in 10 ml heparinized saline.
iltration was carried out to prevent cell clotting and
icroembolization. The resulting cell suspension contained
heterogeneous population of progenitor cells. More than
0% of the cells show EPCs characteristics demonstrated by
il-acetylated low-density lipoprotein (Molecular Probes,
ugene, Oregon) uptake and lectin (UEA-1, Sigma)
inding, as we previously described (20–22). They were
urther documented by showing the expression of vascu-
ar epithelium-cadherin (81  7.9%), kinase-insert
omain-containing receptor (80  8.2%), CD34 (28.7 
.9%), and AC133 (17.1  8.1%) by flow cytometry. The
umber of EPCs was evaluated by an independent investi-
ator. Ten milliliters of EPCs suspension (injected cells, mean
SD 1.1  0.6  107, range 0.4 to 2.2  107) was directly
ntravenously infused into the cell infusion group of patients for
bout 5 min.
tatistical analysis. Our earlier observational study had
hown a 50-m increase in exercise capacity with cell infu-
ion. On the basis of this result, we calculated that we would
equire a sample size of 26 patients to show a 50-m
mprovement on the primary end point 6-min walk distance
ith 80% statistical power. To allow for missing observa-
ions and random differences in the recruited patient pop-
lation, 3 additional patients were added per group. There-
ore, we proceeded with an objective of enrolling 32 patients
ith an interim analysis after 28 patients completed the
tudy. The intention-to-treat principle was applied in the
nalysis, and for missing observations, the last observation
arried forward was done. Data are presented as mean SD
nd 95% confidence intervals. Continuous variables between
he 2 groups were analyzed using independent-samples t
est. Discrete variables between the 2 groups were compared
sing the Fisher exact probability test. A p value of 0.05
2-sided) was considered to indicate statistical significance.
Vll statistical analyses were performed using SPSS version
2.0 (SPSS Inc., Chicago, Illinois).
esults
etween December 15, 2003, and June 30, 2005, 33
atients with IPAH were informed in detail about the
rocedure of EPC transplantation. Informed consent was
btained from 31 patients, who were enrolled into the trial,
hereas 2 patients refused to take part in the trial without
iving any explanation.
All enrolled patients had a mean pulmonary artery pres-
ure 30 mm Hg. Of the 31 patients, 16 were randomized
o conventional therapy (conventional therapy group) and
5 to cell infusion plus conventional therapy (cell infusion
roup). The demographic and baseline characteristics of 2
roups are shown in Table 1. The conventional therapy and
ell infusion groups were well matched with respect to
emographic and baseline characteristics.
One patient in the conventional therapy group opted out
f the study 3 weeks after randomization. This was not the
esult of any serious adverse effect of medication. No
ymptoms, including algor, fever, presyncope, shortness of
reath, hypotension, and increased jugular venous disten-
ion, were occurred in the per-injection period. The number
nd nature of adverse events in drug administration (listed
n Table 2) were similar between the 2 groups.
emographic and Baselineharacteristics of the Patients in 2 Groups
Table 1 Demographic and BaselineCharacteristics of the Patients in 2 Groups
Characteristics
Conventional
Therapy
(n  16)
Cell
Infusion
(n  15) p Value
Age, yrs 36 9 35 12 NS
Gender, n
Male 4 4 NS
Female 12 11 NS
NYHA functional class, n
2 5 5 NS
3 11 10 NS
Duration of symptoms, months 24 11 25 9 NS
Medication, n
Anticoagulant agents 15 14 NS
Calcium antagonists 13 13 NS
Nitrates 9 8 NS
Digitalis 4 3 NS
Diuretics 1 1 NS
Prostaglandin E1 11 10 NS
Sildenafil 6 5 NS
Exercise capacity, m 264 42 263 42 NS
Mean pulmonary artery
pressure, mm Hg
58 9 57 10 NS
Pulmonary vascular resistance,
dyne·s·cm5
1,067 220 1,091 340 NS
Cardiac output, l/min 3.7 0.6 3.7 0.5 NSalues are mean  SD or number of patients.
NS  not significant; NYHA  New York Heart Association.
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April 10, 2007:1566–71 Progenitor Cells and Pulmonary HypertensionThe changes in the exercise capacity and hemodynamic
ariables from baseline to week 12 are listed in Table 3.
fter 12 weeks of follow-up, the mean distance walked in 6
in was increased by 48.2 m in the cell infusion group
from 263 42 m to 312 34 m), and an increase of 5.7 m
ccurred in the conventional therapy group (from 264 
2 m to 270  44 m), with a mean difference of 42.5 m
95% confidence interval 28.7 to 56.3 m; p  0.001).
Comparisons of the 2 groups showed that the patients in
he cell infusion group also had significant improvement in
ean pulmonary artery pressure, pulmonary vascular resis-
ance, and cardiac output. The mean changes in mean
ulmonary artery pressure for the cell infusion and conven-
ional therapy groups were 4.5 and 0.4 mm Hg,
espectively (p  0.001), the mean changes in pulmonary
ascular resistance were 185.4 and 27.8 dyne·s·cm5,
espectively (p  0.002), and the mean changes in cardiac
utput were 0.38 and 0.06 l/min, respectively (p  0.021).
iscussion
o the best of our knowledge, this is the first pilot clinical
tudy to assess the safety and efficacy of transplantation of
utologous adult EPCs from peripheral blood in patients
ith IPAH. Here were present preliminary clinical data
uggesting that transplantation of EPCs was feasible and
afe in the patients. The intravenous infusion of EPCs was
ssociated with increases in the 6-min walk distance and
requency of Adverseffects During th Trial Period*
Table 2 Frequency of AdverseEffects During the Trial Period*
Effects
Conventional
Therapy
(n  16)
Cell
Infusion
(n  15) p Value
Backache 3 1 0.600
Chest pain 2 4 0.378
Headache 3 1 0.600
Leg pain 1 3 0.333
Insomnia 4 2 0.394
Numbness of hands and feet 0 2 0.226
Anorexia 5 3 0.685
Nausea and vomiting 4 1 0.333
Abdominal discomfort 2 0 0.484
Constipation 3 1 0.600
Diarrhea 2 4 0.378
Giddiness 4 2 0.394
Number of patients with adverse event.
hanges in the Exercise Capacity and Hemodynamic Variables From
Table 3 Changes in the Exercise Capacity and Hemodynamic V
Change From
Cell Infusion
6-min walk distance (m) 48.2 17.1
Mean pulmonary artery pressure (mm Hg) 4.5 3.4
Pulmonary vascular resistance (dyne·s·cm5) 185.4 150.8
Cardiac output (l/min) 0.38 0.43Changes from baseline are presented as mean SD; 95% confidence intervals are for comparisons betwmprovements in hemodynamics. The 6-min walk test is a
eliable tool for the assessment of exercise capacity in
atients with IPAH (2,23). It is suggested that the trans-
lantation of autologous EPCs may have beneficial effects
n exercise capacity and pulmonary hemodynamics in pa-
ients with IPAH.
Pulmonary vascular endothelial dysfunction was thought
o play a major role in the initiation and development of
PAH (5,6). This endothelial dysfunction ultimately repre-
ents an imbalance between the magnitude of injury and the
apacity for repair (7). There is strong evidence showing
hat EPCs may play an important role in endothelium
aintenance, being implicated in both re-endothelialization
nd neovascularization (8–10,24–27). The possibility for
nfusion of autologous EPCs has been explored recently for
he neovascularization and repair of ischemic organs. A
ecent study performed in patients with limb ischemia
howed that intramuscular injection into the gastrocnemius
f progenitor cells derived from bone marrow resulted in
ignificant improvements in limb perfusion (14). Other
linical studies described the capacity of ex vivo expanded
utologous EPCs from blood and/or bone marrow for the
epair of human myocardium after infarction (15,16).
Therefore, transplanted EPCs may replenish endothelial
ells, which could enhance the capacity for endothelial
epair. Indeed, green fluorescent protein-expressing EPCs
ere incorporated into pulmonary arterioles and capillaries
n rats and differentiated into mature endothelial cells 3 days
fter transplantation (11). Zhao et al. (12) reported that
one marrow-derived EPCs are involved in vascular regen-
ration in experimental pulmonary arterial hypertension. In
xperimental rats, the delivery of syngeneic endothelial-like
rogenitor cells from bone marrow nearly completely pre-
ented the increase in pulmonary systolic pressures at 3
eeks after monocrotaline (12). Similarly, the delivery of
hese progenitor cells significantly reduced right ventricular
ypertrophy (12). In rats receiving cells, there was a marked
mprovement in the appearance of the lung microvascula-
ure, with preservation of arteriolar continuity and enhanced
apillary perfusion (12). In addition, in experimental dogs
ith dehydromonocrotaline-induced pulmonary hyperten-
ion, transplantation of autologous EPCs from peripheral
lood gave significant improvements in mean pulmonary
rtery pressure, cardiac output, and pulmonary vascular
esistance (13). Histologic evaluation showed both improve-
seline to Week 12*
les From Baseline to Week 12*
line
Mean Difference 95% Confidence Intervalentional Therapy
5.7 20.3 42.5 28.7 to 56.3
0.4 2.4 4.0 6.2 to1.9
27.8 98.0 157.6 250 to65
0.06 0.30 0.32 0.05 to 0.59Ba
ariab
Base
Conv
een the 2 groups. A confidence interval that does not contain zero indicates statistical significance.
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Progenitor Cells and Pulmonary Hypertension April 10, 2007:1566–71ents in the medial thickness of the small pulmonary artery
nd neovascularization of the lung tissue (13). On the other
and, Nagaya et al. (11) reported that the relatively small
enefit could be obtained in response to EPCs therapy in
onocrotaline-induced pulmonary hypertension in rats. It
eems that the result might not reflect the true therapeutic
otential of this cell therapy because these cells were isolated
rom human cord blood and used in a rat model. Because of
mportant interspecies differences, these xenogenic cells may
ot be as well suited for pulmonary vascular repair as
utologous progenitor cells (28). It is suggested that autol-
gous EPCs may be more suitable for pulmonary vascular
epair than xenogenic cells. In the present study, we seemed
o transform the results from animal models to a safe clinical
etting.
However, what remains unknown is how many cells are
eeded or how often cell transplantation may be more
uitable for pulmonary vascular repair in patients with
PAH. A critical question for the EPCs therapy is the
umber of cells (7). One of the approaches for overcoming
his problem is using umbilical cord blood (26). Another is
obilizing EPCs by cytokines, growth factors, or drugs
21,27,29). Furthermore, recent studies have shown a sig-
ificant expansion of EPCs after ex vivo transfection with
denovirus-encoding VEGF, and VEGF gene transfer in
ivo has been shown to mobilize EPCs in human subjects
30,31). Apparently, these include the need for viral or other
ectors to deliver the genes, problems with short biological
alf-lives of the gene products, problems delivering the
recise dose required, and problems with significant safety
oncerns (32). Overall, potent expansion of EPCs ex vivo
ill be required in the future.
Another major question is how to deliver the cells most
fficiently. In the present trial, EPCs were directly intrave-
ously infused into the patients with IPAH. Intravenously
dministered hematopoietic cells have been shown to be
ttracted to sites of cerebral injury (33). Kawamoto et al.
34) also reported that intravenously injected EPCs accu-
ulated in ischemic myocardium after acute myocardial
nfarction. In addition, intravenously administered EPCs
ere incorporated into pulmonary arterioles and capillaries
n rats and differentiated into mature endothelial cells (11).
hese findings suggest that progenitor cells have the ability
o “sense” injured tissues. On the other hand, it was reported
hat the lung parenchyma of pulmonary hypertension model
ogs was injected with autologous EPCs using a broncho-
cope (13). Up to the present, it remains unknown whether
nfusion into the lung parenchyma has more beneficial
ffects than an intravenous administration on pulmonary
rterial hypertension in human EPC transplantation.
Primum non nocere (first do no harm) is, as always, our
verriding concern (32). Fortunately, there were not any
evere complications related to cell infusion during this
tudy. Autologous cell therapy begins with the premise that
ellular repair occurs naturally in the human body and that
nhancing the process should be safe. However, one theo- fetical safety concern regarding the intravenous delivery
oute was that cells administered this way may result in
ulmonary arterial or arteriolar obstruction. Another major
afety concern was the possibility of ex vivo contamination
f the specimen. Infected or contaminated cells could
otentially lead to devastating consequences (32). As such,
ll cell trial protocols should use good manufacturing
ractice facilities to minimize the risk.
tudy limitations. The major limitation of this study was
hat it was not a double-blind, placebo-controlled trial. The
lacebo effect of an uncontrolled, unblended trial may be
ignificant, particularly with regard to exercise capacity. The
thics review board refused to perform a double-blind,
lacebo-controlled trial. If there were a blinded control
roup in the clinical study, 250 ml of venous blood should
e collected from all control patients. However, the valued
lood in essence had to be thrown away afterward; there-
ore, we could not design this study as a double-blind,
lacebo-controlled trial because of ethical considerations.
ortunately, both the walk test and right heart catheteriza-
ion were administered by personnel blinded to the study
rotocol.
Second, acute hemodynamic changes, which constitute
vidence of vasoreactivity, were not always examined, and
alcium channel blockers were usually administered empir-
cally by respective physicians at our center. Most of the
atients were on calcium antagonists, and the baseline data
oncerning pulmonary vascular reactivity were not provided
n this work. In fact, calcium channel blockers have sus-
ained hemodynamic improvement in a small subset
25%) of the patients. In addition, there may be a
otential imbalance in the groups between responders to
alcium channel blockers, and so the observed effects in the
resent study may be confounded.
Third, the trial was conducted on a small number of
atients with IPAH enrolled in this study, and the
ollow-up duration was relatively short. Some future studies
ith larger patient numbers will be required to establish
ong-term safety and efficacy of the cell infusion.
Finally, although EPCs effects in IPAH patients may be
elated to endothelium repair and neovascularization, the
resent clinical study cannot directly disclose the cellular
echanisms associated with the efficacy in patients with
PAH. In addition, we expanded circulating EPCs ex vivo,
hich predominantly showed expression of endothelial
arker proteins but may also contain contaminating other
rogenitor cell populations.
onclusions
aken together, intravenous infusion of autologous EPCs
eemed to be feasible and safe, and might beneficially affect
xercise capacity and pulmonary hemodynamics in patients
ith IPAH, suggesting a new therapeutic option for pa-
ients with IPAH. Our data also provide enough proof for
urther investigation of EPCs and its role in IPAH patients.
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